ASCO GI 2018: Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)